Agilent Technologies Inc. (NYSE: A) is pleased to announce its innovative technology role in supporting the testing of accuracy and reliability in Autolus Therapeutics’ FDA approval for AUCATZYL?, a recently approved CAR T therapy. Agilent xCELLigence Real-Time Cell Analysis (RTCA) technology was utilized in the research and development of potency assays for CAR T therapy by Autolus Therapeutics. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis capabilities, Agilent supported Autolus's efforts in establishing robust analytical methods.

Dr. Xiaobo Wang, Vice President and General Manager of the Cell Function and Phenotyping Business at Agilent stated, "Agilent is honored to have contributed to this development in cancer treatment. The collaboration between Agilent and Autolus highlights the importance of innovative technologies and cooperative efforts in advancing cancer therapies."

David Brochu, Chief Technical Officer at Autolus Therapeutics added, "Agilent's support was invaluable in our journey to FDA approval. Agilent’s state-of-the-art xCELLigence RTCA technology facilitated the accuracy, reliability and precision of our potency analytical procedure."

The xCELLigence Real-Time Cell Analysis (RTCA) technology is a cutting-edge platform that continuously monitors cell behavior in real-time without using labels or dyes. This technology measures electrical impedance to provide dynamic information on cell numbers, viability, and morphology. Unlike traditional endpoint assays, xCELLigence RTCA offers real-time insights, enabling more accurate and timely decision-making in drug development. Its ability to deliver continuous, real-time data sets it apart in the market, providing researchers with a deeper understanding of cellular responses and enhancing the development of effective therapies.

Agilent is committed to advancing scientific innovation and supporting groundbreaking therapies that enhance health outcomes. To learn more about Agilent’s real-time cell analysis solutions, visit Agilent Cell Analysis.

# # #

 This press release was updated on June 11 to clarify Agilent’s support in
the assay development for Autolus Therapeutics’ CAR T therapy, AUCATZYL?.